NGL Fine-Chem Limited (NGLFINE.NS)
INR 2040.45
(3.11%)
INR 2040.45
(3.11%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 307.22 Million INR | 35.64% |
| 2022 | 226.5 Million INR | -22.85% |
| 2021 | 293.57 Million INR | 104.65% |
| 2020 | 143.45 Million INR | -48.46% |
| 2019 | 278.32 Million INR | 5.53% |
| 2018 | 263.73 Million INR | 4.73% |
| 2017 | 251.8 Million INR | 36.92% |
| 2016 | 183.91 Million INR | 72.89% |
| 2015 | 106.37 Million INR | -6.09% |
| 2014 | 113.27 Million INR | -19.62% |
| 2013 | 140.93 Million INR | 35.89% |
| 2012 | 103.71 Million INR | 29.68% |
| 2011 | 79.97 Million INR | 45.34% |
| 2010 | 55.02 Million INR | 37.29% |
| 2009 | 40.07 Million INR | 31.36% |
| 2008 | 30.51 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q4 | 307.22 Million INR | -52.08% |
| 2023 Q3 | 641.08 Million INR | 142.27% |
| 2023 FY | 307.22 Million INR | 35.64% |
| 2023 Q1 | 525.02 Million INR | 131.8% |
| 2023 Q2 | 264.61 Million INR | -49.6% |
| 2022 Q1 | 295.49 Million INR | 0.65% |
| 2022 Q3 | 452.58 Million INR | 159.39% |
| 2022 Q4 | 226.5 Million INR | -49.95% |
| 2022 FY | 226.5 Million INR | -22.85% |
| 2022 Q2 | 174.48 Million INR | -40.95% |
| 2021 Q1 | 338.49 Million INR | 135.97% |
| 2021 Q3 | 399.15 Million INR | 114.75% |
| 2021 Q4 | 293.57 Million INR | -26.45% |
| 2021 Q2 | 185.87 Million INR | -45.09% |
| 2021 FY | 293.57 Million INR | 104.65% |
| 2020 Q2 | 173.11 Million INR | 25.37% |
| 2020 FY | 143.45 Million INR | -48.46% |
| 2020 Q4 | 143.45 Million INR | -47.66% |
| 2020 Q3 | 274.09 Million INR | 58.33% |
| 2020 Q1 | 138.08 Million INR | -50.39% |
| 2019 Q2 | 202.75 Million INR | 71.42% |
| 2019 Q1 | 118.28 Million INR | -55.15% |
| 2019 Q3 | 177.97 Million INR | -12.22% |
| 2019 FY | 278.32 Million INR | 5.53% |
| 2019 Q4 | 278.32 Million INR | 56.38% |
| 2018 FY | 263.73 Million INR | 4.73% |
| 2018 Q4 | 263.73 Million INR | 131.62% |
| 2018 Q3 | 113.86 Million INR | -54.89% |
| 2018 Q2 | 252.43 Million INR | 147.55% |
| 2018 Q1 | 101.97 Million INR | -59.5% |
| 2017 Q4 | 251.8 Million INR | 206.46% |
| 2017 Q1 | 70.46 Million INR | -68.88% |
| 2017 FY | 251.8 Million INR | 36.92% |
| 2017 Q3 | 82.16 Million INR | -60.04% |
| 2017 Q2 | 205.62 Million INR | 191.84% |
| 2016 Q3 | 64.46 Million INR | -33.17% |
| 2016 FY | 183.91 Million INR | 72.89% |
| 2016 Q4 | 226.4 Million INR | 251.21% |
| 2016 Q2 | 96.45 Million INR | 84.59% |
| 2016 Q1 | 52.25 Million INR | -50.88% |
| 2015 Q2 | 107.31 Million INR | 172.56% |
| 2015 FY | 106.37 Million INR | -6.09% |
| 2015 Q1 | 39.37 Million INR | -57.66% |
| 2015 Q4 | 106.37 Million INR | 110.44% |
| 2015 Q3 | 50.55 Million INR | -52.9% |
| 2014 FY | 113.27 Million INR | -19.62% |
| 2014 Q4 | 92.98 Million INR | 0.0% |
| 2014 Q2 | 95.08 Million INR | 732.92% |
| 2014 Q1 | 11.41 Million INR | -91.9% |
| 2013 Q3 | 8.54 Million INR | -92.31% |
| 2013 FY | 140.93 Million INR | 35.89% |
| 2013 Q1 | 15.28 Million INR | -85.26% |
| 2013 Q2 | 111.15 Million INR | 627.0% |
| 2013 Q4 | 140.93 Million INR | 1548.91% |
| 2012 Q4 | 103.71 Million INR | 0.0% |
| 2012 FY | 103.71 Million INR | 29.68% |
| 2011 Q4 | 79.97 Million INR | 0.0% |
| 2011 FY | 79.97 Million INR | 45.34% |
| 2010 FY | 55.02 Million INR | 37.29% |
| 2009 FY | 40.07 Million INR | 31.36% |
| 2008 Q4 | 30.51 Million INR | 0.0% |
| 2008 FY | 30.51 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott India Limited | -20.51 Billion INR | 101.498% |
| Cipla Limited | -3.15 Billion INR | 109.736% |
| Gland Pharma Limited | -14.67 Billion INR | 102.094% |
| GlaxoSmithKline Pharmaceuticals Limited | -674.11 Million INR | 145.575% |
| Kopran Limited | 850.3 Million INR | 63.869% |
| Marksans Pharma Limited | -4.29 Billion INR | 107.153% |
| Pfizer Limited | -19.52 Billion INR | 101.574% |
| Sanofi India Limited | -3.87 Billion INR | 107.928% |
| SMS Pharmaceuticals Limited | 2.44 Billion INR | 87.438% |
| TTK Healthcare Limited | -7.52 Billion INR | 104.085% |